Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

There has been some controversy on the role of taxanes in combination with platinum for the treatment of ovarian cancer. In the current report, patients who relapsed after a disease-free interval of 6 months or more were randomized in 2 large, multicenter trials conducted in Europe to receive either platinum (or typical platinum-based regimens) or paclitaxel plus platinum.

Platinum-Paclitaxel As Second-Line Chemotherapy for Relapsed Ovarian Cancer